The number of cases in contracted medical institution of tella
Clinical experiences with dendritic cell vaccine therapy in approximately 10,800 patients
One of Tella’s cancer vaccines, the dendritic cell vaccine therapy, has been provided to approximately 10,800 patients in 39 medical institutions around Japan, as of the end of September, 2016.
In addition, patient data were analyzed in collaboration with not only doctors from our partner medical institutions but also those from university hospitals to provide more beneficial therapies to patients.
In the journal of American Pancreatic Association "Pancreas", the effects of dendritic cell vaccines with anti-cancer agents were observed in about 35% (17/49) patients of advanced panceratic cancer (see below).